Abstract
BackgroundTumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often rare...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have